New drug trial targets painful skin condition

NCT ID NCT04856930

Completed Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether a new drug called imsidolimab could reduce painful lumps and sores in people with hidradenitis suppurativa (HS), a chronic inflammatory skin disease. 149 adult participants with moderate to severe HS were randomly assigned to receive either the drug or a placebo for 16 weeks. Researchers measured changes in the number of painful lesions and tracked side effects to see if the treatment was effective and safe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Site 10-101

Fort Gratiot, Michigan, 48059, United States
Site 10-102

Sacramento, California, 95817, United States
Site 10-103

Portsmouth, New Hampshire, 03801, United States
Site 10-104

Fountain Valley, California, 92708, United States
Site 10-105

Norfolk, Virginia, 23502, United States
Site 10-106

Spokane, Washington, 99202, United States
Site 10-107

Largo, Florida, 33770, United States
Site 10-108

Birmingham, Alabama, 35224, United States
Site 10-109

Coral Gables, Florida, 33134, United States
Site 10-110

Sandy Springs, Georgia, 30328, United States
Site 10-111

Tampa, Florida, 33607, United States
Site 10-112

Pflugerville, Texas, 78660, United States
Site 10-113

Greenville, South Carolina, 29615, United States
Site 10-115

Warwick, Rhode Island, 02886, United States
Site 10-117

San Antonio, Texas, 78213, United States
Site 10-118

Houston, Texas, 77056, United States
Site 10-119

Northridge, California, 91324, United States
Site 11-101

Saint-Jérôme, Quebec, J7Z 7E2, Canada
Site 11-102

Markham, Ontario, L3P 1X3, Canada
Site 11-103

Cobourg, Ontario, K9A 0Z4, Canada
Site 11-105

Québec, Quebec, G1N 4V3, Canada
Site 11-106

Calgary, Alberta, T2J7E1, Canada
Site 30-103

Ossy, Silesian Voivodeship, 42-624, Poland
Site 30-104

Rzeszów, Podkarpackie Voivodeship, 35-055, Poland
Site 30-106

Olsztyn, 10-229, Poland
Site 30-107

Krakow, Malopolska, 30-074, Poland
Site 30-108

Katowice, Silesian Voivodeship, 40-611, Poland
Site 30-109

Lodz, 90-265, Poland
Site 59-102

Tbilisi, 112, Georgia
Site 59-103

Tbilisi, 160, Georgia
Site 59-104

Tbilisi, 159, Georgia
Site 59-105

Tbilisi, 160, Georgia
Site 59-106

Batumi, 6000, Georgia
Site 59-107

Tbilisi, 162, Georgia

Conditions

Explore the condition pages connected to this study.

HIDRADENITIS SUPPURATIVA